EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Enzychem Lifesciences Corporation is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for inflammatory diseases, oncology, and severe respiratory conditions. The company's primary focus is its lead candidate, EC-18 (Mosedipimod), an oral immunomodulator designed to target fundamental inflammation pathways. Its development pipeline addresses significant unmet medical needs, including chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), and acute radiation syndrome (ARS). In addition to its research and development in new drugs, the company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-06-10 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 21.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 93.4 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.9 KB
2025-03-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.5 MB
2025-03-12 00:00
Major Shareholding Notification
신탁계약에의한취득상황보고서
Korean 49.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 264.6 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 216.5 KB
2025-03-06 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.8 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.3 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MBX Biosciences, Inc. Logo
Developing novel peptide therapies for underserved endocrine and metabolic disorders.
United States of America
MBX
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea
233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan
4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece
MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea
054180
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America
MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany
MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France
MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan
2370
Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1

Talk to a Data Expert

Have a question? We'll get back to you promptly.